Market Overview

UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, $25 PT; Risk-Mitigated Opportunity

Related AMRN
Week Concludes With S&P 500 Below 2,000; Dow Below 17,000
Dow Falls Over 100 Points; Ulta Salon Shares Jump After Earnings Report
Related AMRN
Conversant Shares Rise On Acquisition News; Health Care REIT Drops
Markets Drop; Darden Adjusted Profit Beats Street View

Aegis Capital said on Monday that it initiated coverage on Amarin Corporation (NASDAQ: AMRN) with a Buy rating and a price target of $25.

Aegis Capital said, "In our view, Amarin constitutes one of the most risk-mitigated opportunities in the biotechnology sector, as the firm's lead product candidate has already successfully demonstrated safety and efficacy in two randomized, placebo-controlled Phase 3 clinical trials. These studies were conducted under Special Protocol Assessments (SPAs) from the U.S. FDA."

Amarin Corporation closed at $15.12 on Friday.

Latest Ratings for AMRN

DateFirmActionFromTo
May 2014CitigroupDowngradesBuyNeutral
Feb 2014Aegis CapitalMaintainsHold
Jan 2014MKM PartnersDowngradesBuyNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters